ABVC Biopharma Working Capital

What does ABVC Biopharma do? American BriVision (Holding) Corp. is a clinical stage biopharmaceutical company focused on developing new drugs and medical devices. It utilizes licensed technology to enhance pre-existing pharmaceutical products for cancer treatments and other diseases, with a focus on identifying responsive patients. The company operates through five compounds licensed from BioLite Inc.: ABV-1501, ABV-1502, ABV-1503, ABV-1504, and ABV-1505. As of September 30, 2016, the company had not generated any revenues from its operations. The firm's revenue model relies on the development and commercialization of its licensed compounds. It partners with BioLite Inc. for the technology and compounds, which it aims to enhance and commercialize in various markets. The company targets cancer indications and other diseases for its pharmaceutical products, seeking to identify patients who may respond to these treatments. The clinical-stage nature of its operations means it is still in the research and development phase without current revenue streams. American BriVision (Holding) Corp. is headquartered in Fremont, California, and employs 34 full-time employees. It went public via IPO on November 9, 2004. The company's focus on enhancing pre-existing drugs through licensed technology positions it for future revenue generation once its compounds reach commercialization. However, as of the latest data, it has not yet generated any revenue from its operations. ABVC Biopharma is one of the most popular companies on Eulerpool.